STOCK TITAN

Aptose Biosciences (APTO) Stock News, Oct 2023-Mar 2024

APTO

Aptose Biosciences Inc. reports company developments as a clinical-stage precision oncology company focused on tuspetinib-based therapy for acute myeloid leukemia. News commonly centers on the Phase 1/2 TUSCANY trial of tuspetinib in combination with venetoclax and azacitidine for newly diagnosed AML, including safety reviews, dose-escalation updates, remission data, and conference presentations.

Company updates also cover operating and financial results, financing facilities, research collaborations, auditor changes, and exchange-listing compliance matters. These disclosures frame Aptose around clinical development, capital resources, governance, and the public-company requirements tied to its common shares.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.00%
Tags
private placement offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.21%
Tags
private placement offering
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.79%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.38%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.30%
Tags
conferences earnings

FAQ

What is the current stock price of Aptose Biosciences (APTO)?

Aptose Biosciences (APTO) last closed at $1.71.